Safety and tolerability of rufinamide in children with epilepsy: A pooled analysis of 7 clinical studies

James W. Wheless, Joan Conry, Gregory Krauss, Allison Mann, Antonia Lopresti, Milind Narurkar

Research output: Contribution to journalArticlepeer-review


Rufinamide is a novel antiepileptic agent recently approved in the United States for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome. To help inform clinical decision making, the authors analyzed safety and tolerability data from the entire pediatric population in the rufinamide epilepsy clinical development program. The analysis population comprised 212 rufinamide-treated (age range 3-16 years) and 197 placebo patients (age range 4-17 years) in the double-blind studies, and 391 patients receiving rufinamide in the double-blind and/or open-label extensions. The most common adverse effects observed in rufinamide-treated patients in the double-blind studies were somnolence, vomiting, and headache. Changes in laboratory values, vital signs, and weight were generally clinically insignificant. This pooled analysis of data from pediatric patients in clinical studies of rufinamide for the treatment of seizures, mainly as adjunctive therapy, suggests a favorable safety and tolerability profile in this patient population.

Original languageEnglish (US)
Pages (from-to)1520-1525
Number of pages6
JournalJournal of child neurology
Issue number12
StatePublished - Dec 1 2009


  • Epilepsy
  • Lennox-Gastaut syndrome
  • Rufinamide
  • Safety
  • Seizures

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Clinical Neurology


Dive into the research topics of 'Safety and tolerability of rufinamide in children with epilepsy: A pooled analysis of 7 clinical studies'. Together they form a unique fingerprint.

Cite this